Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonists

Neuropharmacology

Volumn 44, Issue 1, 2003, Pages 125-131

  Langer, I ^a   Vertongen, P ^a   Perret, J ^a   Waelbroeck, M ^a   Robberecht, P ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

GPCR mutations; VIP; VIP agonist; VIP antagonist; VPAC1 receptor

Indexed keywords

ADENYLATE CYCLASE; ASPARTATE 196; ASPARTIC ACID DERIVATIVE; LYSINE; LYSINE 195; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HYDROGEN BOND; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; WILD TYPE;

EID: 0037247242     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00233-2     Document Type: Article

References (22)

1. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. British Journal of Pharmacology. 125:1998;924-947.
2. Couvineau A., Rouyer-Fessard C., Darmoul D., Maoret J.J., Carrero I., Ogier-Denis E., Laburthe M. Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochemical and Biophysical Research Communications. 200:1994;769-776.
3. Di Paolo E., De Neef P., Moguilevsky N., Petry H., Bollen A., Waelbroeck M., Robberecht P. Contribution of the second transmembrane helix of the secretin receptor to the positioning of secretin. FEBS Letters. 424:1998;207-210.
4. Di Paolo E., Vilardaga J.P., Petry H., Moguilevsky N., Bollen A., Robberecht P., Waelbroeck M. Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality. Peptides. 20:1999;1187-1193.
5. Dickinson T., Mitchell R., Robberecht P., Fleetwood-Walker S.M. The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy. Neuropharmacology. 38:1999;167-180.
6. Du K., Nicole P., Couvineau A., Laburthe M. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production. Biochemical and Biophysical Research Communications. 230:1997;289-292.
7. Gomariz R.P., Martinez C., Abad C., Leceta J., Delgado M. Immunology of VIP: a review and therapeutical perspectives. Current Pharmaceutical Design. 7:2001;89-111.
8. Gourlet P., Vandermeers A., Vertongen P., Rathe J., De Neef P., Cnudde J., Waelbroeck M., Robberecht P. Development of high affinity selective VIP1 receptor agonists. Peptides. 18:1997;1539-1545.
9. 1 receptor. Peptides. 18:1997;1555-1560.
10. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., Waschek J.A. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacological Review. 50:1998;265-270.
11. Hashimoto H., Ogawa N., Hagihara N., Yamamoto K., Imanishi K., Nogi H., Nishino A., Fujita T., Matsuda T., Nagata S., Baba A. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. Molecular Pharmacology. 52:1997;128-135.
12. Holtmann M.H., Hadac E.M., Miller L.J. Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors. Journal of Biological Chemistry. 270:1995;14394-14398.
13. Langer I., Perret J., Vertongen P., Waelbroeck M., Robberecht P. Vasoactive intestinal peptide (VIP) stimulates [Ca(2+)](i)and cyclic AMPin CHO cells expressing Galpha16. Cell calcium. 30:2001;229-234.
14. MacKenzie C.J., Lutz E.M., McCulloch D.A., Mitchell R., Harmar A.J. Phospholipase C activation by VIP1 and VIP2 receptors expressed in COS 7 cells involves a pertussis toxin-sensitive mechanism. Annals of the New York Academy of Sciences. 805:1996;579-584.
15. Perret J., Van Craenenbroeck M., Langer I., Vertongen P., Gregoire F., Robberecht P., Waelbroeck M. Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue. Biochemical Journal. 362:2002;389-394.
16. Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Analytical Biochemistry. 58:1974;541-548.
17. Simonneaux V., Kienlen-Campard P., Loeffler J.P., Basille M., Gonzalez B.J., Vaudry H., Robberecht P., Pevet P. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland. Neuroscience. 85:1998;887-896.
18. Solano R.M., Langer I., Perret J., Vertongen P., Juarranz M.G., Robberecht P., Waelbroeck M. Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction. Journal of Biological Chemistry. 276:2001;1084-1088.
19. Sreedharan S.P., Patel D.R., Xia M., Ichikawa S., Goetzl E.J. Human vasoactive intestinal peptide1 receptors expressed by stable transfectants couple to two distinct signaling pathways. Biochemical and Biophysical Research Communications. 203:1994;141-148.
20. Vertongen P., Solano R.M., Perret J., Langer I., Robberecht P., Waelbroeck M. Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix. British Journal of Pharmacology. 133:2001;1249-1254.
21. Vilardaga J.P., De Neef P., Di Paolo E., Bollen A., Waelbroeck M., Robberecht P. Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination. Biochemical and Biophysical Research Communications. 211:1995;885-891.
22. Xiao Q., Jeng W., Wheeler M.B. Characterization of glucagon-like peptide-1 receptor-binding determinants. Journal of Molecular Endocrinology. 25:2000;321-335.